Nomura/Instinet Reiterates Buy Rating on Protagonist Therapeutics (PTGX), Expects Upside in PTG-300 Results
Tweet Send to a Friend
Nomura/Instinet analyst Christopher Marai reiterated a Buy rating and $29.00 price target on Protagonist Therapeutics (NASDAQ: PTGX) stating that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
